Compare TAC & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TAC | MMED |
|---|---|---|
| Founded | 1909 | 1983 |
| Country | Canada | United States |
| Employees | 1350 | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.1B |
| IPO Year | N/A | 2026 |
| Metric | TAC | MMED |
|---|---|---|
| Price | $12.99 | $11.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $23.67 | $22.56 |
| AVG Volume (30 Days) | ★ 952.2K | 641.5K |
| Earning Date | 05-06-2026 | 06-03-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $15.99 |
| Revenue Next Year | $6.48 | $10.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.73 | $11.02 |
| 52 Week High | $17.88 | $17.86 |
| Indicator | TAC | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 33.13 |
| Support Level | $12.09 | N/A |
| Resistance Level | $14.00 | $15.80 |
| Average True Range (ATR) | 0.42 | 0.72 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 83.60 | 5.70 |
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse electrical power generation assets in Canada, the United States, and Western Australia. The company has reportable segments namely, Hydro, Wind & Solar, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.